- Home
- IBRX vs FA Comparison
IBRX vs FA Comparison
Compare IBRX & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- FA
- Stock Information
- Founded
- IBRX 2014
- FA 2003
- Country
- IBRX United States
- FA United States
- Employees
- IBRX N/A
- FA N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- FA Business Services
- Sector
- IBRX Health Care
- FA Consumer Discretionary
- Exchange
- IBRX Nasdaq
- FA Nasdaq
- Market Cap
- IBRX 2.3B
- FA 2.8B
- IPO Year
- IBRX N/A
- FA 2021
- Fundamental
- Price
- IBRX $2.76
- FA $15.58
- Analyst Decision
- IBRX Strong Buy
- FA Hold
- Analyst Count
- IBRX 6
- FA 6
- Target Price
- IBRX $9.83
- FA $20.75
- AVG Volume (30 Days)
- IBRX 9.7M
- FA 640.6K
- Earning Date
- IBRX 11-11-2025
- FA 11-11-2025
- Dividend Yield
- IBRX N/A
- FA N/A
- EPS Growth
- IBRX N/A
- FA N/A
- EPS
- IBRX N/A
- FA N/A
- Revenue
- IBRX $56,600,000.00
- FA $1,251,464,000.00
- Revenue This Year
- IBRX $629.94
- FA $84.03
- Revenue Next Year
- IBRX $109.91
- FA $6.00
- P/E Ratio
- IBRX N/A
- FA N/A
- Revenue Growth
- IBRX 4227.22
- FA 65.34
- 52 Week Low
- IBRX $1.83
- FA $12.32
- 52 Week High
- IBRX $7.48
- FA $20.79
- Technical
- Relative Strength Index (RSI)
- IBRX 64.62
- FA 40.64
- Support Level
- IBRX $2.32
- FA $15.47
- Resistance Level
- IBRX $2.67
- FA $16.55
- Average True Range (ATR)
- IBRX 0.14
- FA 0.53
- MACD
- IBRX 0.05
- FA -0.03
- Stochastic Oscillator
- IBRX 72.73
- FA 30.03
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About FA First Advantage Corporation
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.